See more : Reliance Infrastructure Limited (RELINFRA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of X4 Pharmaceuticals, Inc. (XFOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of X4 Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- BEST AGROLIFE LIMITED (BESTAGRO.BO) Income Statement Analysis – Financial Results
- Supreme Infrastructure India Limited (SUPREMEINF.NS) Income Statement Analysis – Financial Results
- Anglo Pacific Group plc (APY.TO) Income Statement Analysis – Financial Results
- Landmark Cars Limited (LANDMARK.BO) Income Statement Analysis – Financial Results
- Amper, S.A. (APMRF) Income Statement Analysis – Financial Results
X4 Pharmaceuticals, Inc. (XFOR)
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.00M | 0.00 | 3.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.99M | 1.89M | 0.00 | 672.00K | 103.00K | 195.00K | 300.00K | 400.00K |
| Gross Profit | -2.00M | -1.99M | -1.89M | 3.00M | -672.00K | 3.40M | -195.00K | -300.00K | -400.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 97.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 72.02M | 61.06M | 50.65M | 41.93M | 30.16M | 30.98M | 28.13M | 17.83M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.51M | 27.02M | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Other Expenses | 0.00 | -6.27M | -3.57M | -2.11M | -1.10M | -85.00K | -16.00K | 104.00K | -77.00K |
| Operating Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Cost & Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Interest Income | 4.58M | 219.00K | 10.00K | 273.00K | 1.20M | 809.00K | 214.00K | 0.00 | 0.00 |
| Interest Expense | 5.78M | 3.99M | 3.64M | 2.69M | 2.15M | 1.04M | 2.08M | 2.52M | 472.00K |
| Depreciation & Amortization | 419.00K | 1.99M | 1.89M | 1.23M | 672.00K | 103.00K | 195.00K | 300.00K | 389.00K |
| EBITDA | -107.52M | -87.57M | -85.11M | -58.07M | -51.70M | -45.89M | -31.60M | -20.16M | -12.35M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,195.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.52M | -87.57M | -85.11M | -59.87M | -51.70M | -45.89M | -36.13M | -24.35M | -14.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,311.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.43M | -6.27M | -3.57M | -2.11M | -1.10M | 2.86M | 2.26M | 6.48M | 1.61M |
| Income Before Tax | -101.09M | -93.84M | -88.68M | -61.98M | -52.81M | -43.02M | -33.88M | -22.98M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -2,066.10% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 78.00K | 28.00K | 17.00K | 148.00K | 3.80M | 3.90M | 1.87M | 2.62M | 395.00K |
| Net Income | -101.17M | -93.87M | -88.70M | -62.13M | -56.60M | -43.02M | -33.88M | -22.98M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -2,071.03% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| EPS Diluted | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| Weighted Avg Shares Out | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
| Weighted Avg Shares Out (Dil) | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
Source: https://incomestatements.info
Category: Stock Reports
What is the projected cash runway for X4 Pharmaceuticals?
X4 Pharmaceuticals Inc (NASDAQ:XFOR) ended the third quarter of 2024 with cash and equivalents of almost $136 million, providing a financial runway into late 2025.
What were X4 Pharmaceuticals’ net revenues in Q3 2024?
Revenue and Cost of Revenue: For the three months ended September 30, 2024 , X4 reported net product revenue of $0.6 million and cost of revenue of $0.2 million related to the sale of XOLREMDI.